Tags

Type your tag names separated by a space and hit enter

Prostate cancer prevention: past, present, and future.
Cancer 2007; 110(9):1889-99C

Abstract

Prostate cancer is the most common male malignancy and the second or third leading cause of cancer death among men in the West. The descriptive epidemiology of prostate cancer suggests that it is a preventable disease. Prevention has the theoretical advantage of not only saving lives, but also reduce the morbidity of radical prostate cancer therapy. This article reviews the past, present, and future of prostate cancer prevention. In particular, the evidence and scientific data of a variety of prevention strategies are reviewed. Strategies reviewed include dietary fat reduction and supplementation with vitamins D and E, and selenium. Dietary intake of soy, green tea, and tomato-rich products (lycopene) are also reviewed. Data regarding pharmacological intervention with cyclo-oxygenease inhibitors, antiestrogens, and in particular 5-alpha reductase inhibitors are reviewed. The results of the Prostate Cancer Prevention Trial including the controversy surrounding higher-grade cancers among men randomized to finasteride are also summarized. Finally, a variety of trial designs as well as a roster of current phase 2 trials are presented. Probably no cancer is being investigated more thoroughly in the context of prevention as prostate cancer in 2007. Definitive answers to pivotal phase 3 trials will be available in the coming 2 to 7 years.

Authors+Show Affiliations

Division of Urology, University Health Network, and Department of Surgery (Urology), University of Toronto, Toronto, Ontario, Canada. neil.fleshner@utoronto.caNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17893870

Citation

Fleshner, Neil, and Alexandre R. Zlotta. "Prostate Cancer Prevention: Past, Present, and Future." Cancer, vol. 110, no. 9, 2007, pp. 1889-99.
Fleshner N, Zlotta AR. Prostate cancer prevention: past, present, and future. Cancer. 2007;110(9):1889-99.
Fleshner, N., & Zlotta, A. R. (2007). Prostate cancer prevention: past, present, and future. Cancer, 110(9), pp. 1889-99.
Fleshner N, Zlotta AR. Prostate Cancer Prevention: Past, Present, and Future. Cancer. 2007 Nov 1;110(9):1889-99. PubMed PMID: 17893870.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prostate cancer prevention: past, present, and future. AU - Fleshner,Neil, AU - Zlotta,Alexandre R, PY - 2007/9/26/pubmed PY - 2007/12/12/medline PY - 2007/9/26/entrez SP - 1889 EP - 99 JF - Cancer JO - Cancer VL - 110 IS - 9 N2 - Prostate cancer is the most common male malignancy and the second or third leading cause of cancer death among men in the West. The descriptive epidemiology of prostate cancer suggests that it is a preventable disease. Prevention has the theoretical advantage of not only saving lives, but also reduce the morbidity of radical prostate cancer therapy. This article reviews the past, present, and future of prostate cancer prevention. In particular, the evidence and scientific data of a variety of prevention strategies are reviewed. Strategies reviewed include dietary fat reduction and supplementation with vitamins D and E, and selenium. Dietary intake of soy, green tea, and tomato-rich products (lycopene) are also reviewed. Data regarding pharmacological intervention with cyclo-oxygenease inhibitors, antiestrogens, and in particular 5-alpha reductase inhibitors are reviewed. The results of the Prostate Cancer Prevention Trial including the controversy surrounding higher-grade cancers among men randomized to finasteride are also summarized. Finally, a variety of trial designs as well as a roster of current phase 2 trials are presented. Probably no cancer is being investigated more thoroughly in the context of prevention as prostate cancer in 2007. Definitive answers to pivotal phase 3 trials will be available in the coming 2 to 7 years. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/17893870/Prostate_cancer_prevention:_past_present_and_future_ L2 - https://doi.org/10.1002/cncr.23009 DB - PRIME DP - Unbound Medicine ER -